Phosphoramide mustard (cyclohexanamine)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Phosphoramide mustard (cyclohexanamine)  纯度: ≥95.0%

Phosphoramide mustard cyclohexanamine 是环磷酰胺 (HY-17420) 的活性代谢物，具有抗肿瘤活性。Phosphoramide mustard cyclohexanamine 能诱导 DNA 损伤。

Phosphoramide mustard (cyclohexanamine)

Phosphoramide mustard (cyclohexanamine) Chemical Structure

CAS No. : 1566-15-0

规格 价格 是否有货 数量
5 mg ￥3400 In-stock
10 mg ￥6000 In-stock
25 mg ￥12500 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

Phosphoramide mustard (cyclohexanamine) 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Cell Cycle/DNA Damage Compound Library
  • Metabolism/Protease Compound Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Anti-Lung Cancer Compound Library
  • Drug Metabolite Library

生物活性

Phosphoramide mustard cyclohexanamine is a biologically active metabolite of Cyclophosphamide (HY-17420), with anticancer activitiy. Phosphoramide mustard cyclohexanamine induces DNA damage[1][2].

体外研究
(In Vitro)

Phosphoramide mustard cyclohexanamine causes cytotoxicity through forming cross-linked DNA adducts which inhibit DNA strand separation during replication[1].
Phosphoramide mustard cyclohexanamine (3-6 μM; 48 hours) reduces cell viability in rat spontaneously immortalized granulosa cells (SIGCs)[1].
Phosphoramide mustard cyclohexanamine (3-6 μM; 24-48 hours) induces DNA adduct formation and ovarian DNA damage[1].
Phosphoramide mustard cyclohexanamine (3-6 μM; 24-48 hours) increases DNA damage responses (DDR) gene mRNA expression levels and DDR proteins[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: SIGCs
Concentration: 0.5 μM, 1 μM, 3 μM, 6 μM
Incubation Time: 48 hours
Result: Reduced cell viability at concentrations of 3 μM and higher.

RT-PCR[1]

Cell Line: SIGCs
Concentration: 3 μM, 6 μM
Incubation Time: 24 hours, 48 hours
Result: Increased DDR gene mRNA expression levels.

Western Blot Analysis[1]

Cell Line: SIGCs
Concentration: 3 μM, 6 μM
Incubation Time: 24 hours, 48 hours
Result: Generally increased DDR proteins.

体内研究
(In Vivo)

Phosphoramide mustard cyclohexanamine (2.1-20.7 mg/kg; i.p.; daily; for 5 days) inhibits subcutaneous tumor growth in rats[2].
Phosphoramide mustard cyclohexanamine exhibits terminal elimination half-lives (rat 15.1 min) following intravenous administration (rat 59.4 mg/kg)[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Rat, subcutaneously implanted Walker 256 carcinosarcoma tumor[2]
Dosage: 2.1 mg/kg, 4.8 mg/kg, 10.4 mg/kg, 20.7 mg/kg
Administration: Intraperitoneal injection, once daily, for 5 consecutive days
Result: Required to produce 50% inhibition of subcutaneous tumor growth with dose of 12 mg/kg.
Animal Model: Rats[2]
Dosage: 86.0 mg/kg (Pharmacokinetic Analysis)
Administration: Intravenous injection
Result: T1/2 (15.1 min).

分子量

320.20

Formula

C10H24Cl2N3O2P
CAS 号

1566-15-0
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

-20°C, protect from light, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
溶解性数据
In Vitro: 

H2O : 100 mg/mL (312.30 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.1230 mL 15.6152 mL 31.2305 mL
5 mM 0.6246 mL 3.1230 mL 6.2461 mL
10 mM 0.3123 mL 1.5615 mL 3.1230 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. Shanthi Ganesan, et al. Phosphoramide mustard exposure induces DNA adduct formation and the DNA damage repair response in rat ovarian granulosa cells. Toxicol Appl Pharmacol. 2015 Feb 1; 282(3): 252–258.

    [2]. S Genka, et al. Brain and plasma pharmacokinetics and anticancer activities of cyclophosphamide and phosphoramide mustard in the rat. Cancer Chemother Pharmacol. 1990;27(1):1-7.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务